MSF welcomes WHA resolution on strengthening diagnostic testing in low- and middle-income countries

MSF warned that access to point-of-care CD4 tests for HIV are under threat because Abbott and Becton Dickinson have decided to stop production

Gilead hikes price while liposomal amphotericin B (L-AmB) for treatment of HIV-related cryptococcal meningitis remains unavailable and unaffordable in countries where it’s most needed

MSF appreciates EC pharma legislation proposal to improve transparency by industry and the granting of compulsory licenses on medicines in the EU.

Access to TB drug bedaquiline, a backbone medicine for drug-resistant TB treatment regimens, remains out of reach for too many

For World Immunization Week 2023, MSF calls on Gavi to expand its policy to catch up young children on missed vaccinations.

With affordable generics likely years away, ViiV must make information public on supply of long-acting cabotegravir and global distribution plan to ensure access for people in high HIV burden low- and middle-income countries

2019 patent challenge by TB survivors, Nandita Venkatesan and Phumeza Tisile, was successful against J&J's secondary patent application for bedaquiline.

MSF called on governments and donors to speed up access to diagnostic tests, and shorter, safer and more effective treatments, for DR-TB.

MSF response to negotiations on an India-EU free trade agreement (FTA) regarding harmful intellectual property (IP) provisions

Gavi's new CEO must prioritise catch-up vaccinations for young children, and more inclusive decision-making.

Ahead of World Neglected Tropical Disease (NTD) Day 30 January, MSF demands improved global response for NTDs, including increased investment.

Ahead of the final hearing on a patent challenge by two TB survivors, MSF urges the Indian Patent Office to reject Johnson & Johnson’s secondary patent application so that other manufacturers may enter the supply chain with more ...

Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of ...

The World Health Organization’s Global Tuberculosis Report 2022 highlights that still only one in three people with drug-resistant tuberculosis is getting treatment, and the treatment success rate for those who do receive treatment ...

MSF calls on ViiV to urgently dismantle barriers to access for long-acting cabotegravir

A MSF report released today finds that two newer TB drugs – bedaquiline and delamanid – going off patent in 2023 presents a critical opportunity to increase access to shorter, safer and better treatment for people with drug-resistant ...

UK IP demands contain provisions that would drastically harm access to affordable, lifesaving generic medicines from India, upon which millions of people around the world rely

MSF reiterates that the price of a full DR-TB treatment course should be no more than US$500 per person.

Due to the high number of countries currently experiencing cholera outbreaks and a shortage of oral cholera vaccine, the International Coordinating Group (ICG) announced today that it will temporarily suspend the standard two-dose ...